Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.

James J McGough1, Caroly S Pataki, Robert Suddath

  • 1David Geffen School of Medicine, 300 UCLA Medical Plaza, Suite 1414, Los Angeles, CA 90095, USA. jmcgough@mednet.ucla.edu

Expert Review of Neurotherapeutics
|July 20, 2005
PubMed
Summary

Dexmethylphenidate extended release offers effective ADHD treatment with a dual-release mechanism for sustained symptom control. This stimulant medication is well-tolerated, showing promise for improved patient convenience and adherence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurofeedback for ADHD: Time to Call It Quits?

The American journal of psychiatry·2022
Same author

Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder.

Journal of the American Academy of Child and Adolescent Psychiatry·2022
Same author

Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.

Journal of the American Academy of Child and Adolescent Psychiatry·2022
Same author

Inhibitory control in youth with Tourette's Disorder, attention-deficit/hyperactivity disorder and their combination and predictors of objective tic suppressibility.

Psychiatry research·2021
Same author

Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder: Cognitive and Electroencephalographic Predictors of Treatment Response.

Journal of the American Academy of Child and Adolescent Psychiatry·2020
Same author

Correction.

The Journal of clinical psychiatry·2019

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Attention Deficit Hyperactivity Disorder (ADHD) treatments are a significant market segment.
  • Stimulant medications are highly effective for ADHD symptoms in children and adults.
  • Extended-release formulations are preferred for convenience and compliance.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of dexmethylphenidate extended release (ER) for ADHD.
  • To assess the pharmacokinetic profile and duration of action of dexmethylphenidate ER.
  • To compare dexmethylphenidate ER to placebo in clinical trials.

Main Methods:

  • Placebo-controlled clinical trials in pediatric and adult ADHD patients.
  • Utilized spheroidal oral drug absorption system (SODAS) technology for dual drug release.

Related Experiment Videos

  • Conducted analog classroom studies to assess duration of effect.

    • Main Results:

    • Dexmethylphenidate ER demonstrated significant efficacy in improving ADHD symptoms.
    • Medication effects were observed for up to 12 hours in analog classroom settings.
    • The side-effect profile was comparable to other stimulants, with diminished appetite and insomnia being most common.

    Conclusions:

    • Dexmethylphenidate ER is an effective and well-tolerated ADHD treatment.
    • Its extended duration of action and favorable tolerability profile support its use.
    • This formulation offers flexibility and convenience for ADHD management.